Cibc World Markets Corp Invests $364,000 in Krystal Biotech, Inc. (NASDAQ:KRYS)

Cibc World Markets Corp bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,321 shares of the company's stock, valued at approximately $364,000.

Several other institutional investors have also made changes to their positions in KRYS. Commonwealth Equity Services LLC boosted its position in shares of Krystal Biotech by 4.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company's stock worth $762,000 after buying an additional 190 shares during the period. Swiss National Bank lifted its stake in Krystal Biotech by 8.4% in the 4th quarter. Swiss National Bank now owns 42,400 shares of the company's stock worth $6,642,000 after acquiring an additional 3,300 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Krystal Biotech by 31.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,054 shares of the company's stock worth $948,000 after acquiring an additional 1,440 shares during the period. Sound View Wealth Advisors Group LLC grew its stake in Krystal Biotech by 18.3% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,420 shares of the company's stock valued at $222,000 after acquiring an additional 220 shares in the last quarter. Finally, AlphaQuest LLC increased its holdings in shares of Krystal Biotech by 116.0% in the 4th quarter. AlphaQuest LLC now owns 3,020 shares of the company's stock valued at $473,000 after purchasing an additional 1,622 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Krystal Biotech Price Performance

Shares of KRYS stock traded up $1.17 on Friday, hitting $183.92. The company's stock had a trading volume of 224,610 shares, compared to its average volume of 289,891. The stock has a market capitalization of $5.30 billion, a price-to-earnings ratio of 61.51 and a beta of 0.87. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The firm's fifty day moving average price is $170.11 and its 200-day moving average price is $173.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business's quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.30 earnings per share. Analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on KRYS. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup lifted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective for the company. Finally, Chardan Capital boosted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $220.00.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).